Current report No. 15/2023 – Statement of the Central Securities Depository of Poland (KDPW) on assimilation of 21,500 C-series shares with the Company’s shares currently traded in the stock exchange

Date prepared: June 15, 2022

Abbreviated name of the issuer: CELON PHARMA S.A.

Subject: Statement of the Central Securities Depository of Poland (KDPW) on assimilation of 21,500 C-series shares with the Company’s shares currently traded in the stock exchange

Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information

Content of the report:

The Management Board of Celon Pharma S.A. (“Company”) hereby announces that on June 14, 2023, the Central Securities Depository of Poland (“KDPW”) presented a statement indicating that it has decided to assimilate 21,500 ordinary C-series bearer shares on June 19, 2023, registered under the ISIN PLCLNPH00080 code, with the Company’s shares currently traded in the stock exchange, registered under the PLCLNPH00015 code.

Therefore, the condition for the introduction of the aforementioned 21,500 C-series shares to trading on the primary market as of June 19, 2023, specified in the Resolution of the Management Board of the Warsaw Stock Exchange, of which the Company informed in its current report No. 14/2023 of June14, 2023, has been met.